clinical trials

Explore Mazdutide (LY3305677), an emerging dual GLP-1 and glucagon receptor agonist peptide designed for profound weight loss and metabolic health.

Discover Orforglipron, an innovative oral non-peptide GLP-1 receptor agonist in Phase 3 trials for obesity and diabetes. Explore benefits and side effects.

Explore Retatrutide, a breakthrough triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors for unprecedented weight loss and metabolic health.

Discover Survodutide (BI 456906), a dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and MASH. Explore its mechanism and side effects.